French biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations.

The agreement will initially be based on Pharnext’s disruptive technological platform, known as Pleotherapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The platform has enabled the discovery of low dose combinations of approved drugs repositioned in a new indication, and aims to develop safer treatments for unmet medical needs.

Pharnext co-founder and CEO Daniel Cohen said: “The R&D collaboration with Galapagos validates the value of Pharnext’s innovative platform, Pleotherapy.

“Moreover, this collaboration will enlarge our product portfolio with drug combinations including also new compounds.”

See Also:

"The R&D collaboration with Galapagos validates the value of Pharnext’s innovative platform, Pleotherapy."

Pharnext said that the agreement with Galapagos demonstrates its ability to reinforce the potential of new candidate drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This agreement will concern therapeutic indications that were primarily envisioned by Galapagos in addition to others that will be identified by Pharnext.

It contains therapeutic indications such as immunoinflammatory and neurodegenerative disorders, which represent potentially substantial markets.

Each of the companies will have priority on indications that were allocated earlier.

Galapagos and Pharnext will jointly own intellectual property with regards to synergistic drug combinations generated by the R&D agreement.

Pharnext currently focuses on neurodegenerative diseases and has two lead products, PXT3003 and PXT864, in clinical development.